SCHEMBL467238

SCHEMBL467238

COc1cc(C[Mg]Br)cc(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
CYP19A1 P11511 1/20 0.42
CALM1 P0DP23 3/20 0.40
AKR1B1 P15121 1/20 0.40
CYP1A1 P04798 2/20 0.39
CYP1B1 Q16678 2/20 0.39
TSHR P16473 2/20 0.39
PTGS2 P35354 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
MAPK1 P28482 1/20 0.38
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38656636 0.86 CYP4F2 (0.38) ALDH1A1CYP19A1CALM1TSHRPTGS2
SCHEMBL1006647 0.79 TAAR1 (0.55)
SCHEMBL2390804 0.77 ALDH1A1 (0.50) ALDH1A1CYP19A1CALM1AKR1B1CYP1A1
SCHEMBL363725 0.77 IDO1 (0.52) ALDH1A1CALM1TSHR
SCHEMBL627823 0.73 ALDH1A1 (0.58) ALDH1A1CYP19A1CALM1AKR1B1CYP1A1
SCHEMBL9491787 0.72 CYP19A1 (0.68) ALDH1A1CYP19A1CALM1AKR1B1CYP1A1
SCHEMBL5252553 0.72 ALDH1A1 (0.65) ALDH1A1CYP19A1CALM1AKR1B1CYP1A1
SCHEMBL467237 0.71 ALDH1A1 (0.55) ALDH1A1CYP19A1CALM1AKR1B1CYP1A1
1,3,5-Trimethoxybenzene SCHEMBL28493 0.71 ALDH1A1 (1.00) ALDH1A1CYP19A1CYP1A1CYP1B1PTGS2
SCHEMBL88823 0.70 ALDH1A1 (0.61) ALDH1A1CYP19A1CALM1AKR1B1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105579438-B Compounds and methods for skin repair 阿勒根公司 2019-12-06 CN disclosed
US-9546162-B2 Compounds and methods for skin repair ALLERGAN, INC. (US) 2017-01-17 US disclosed
EP-3049392-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR ALLERGAN, INC. (US) 2016-08-03 EP disclosed
US-20150094330-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR ALLERGAN INC (US) 2015-04-02 US disclosed
WO-2015048553-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR ALLERGAN, INC. (US) 2015-04-02 WO disclosed
EP-2399577-A1 Use of N-containing spirocompounds for the enhancement of cognitive function Adolor Corporation (US) 2011-12-28 EP disclosed
US-8022060-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2011-09-20 US disclosed
US-20110218186-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2011-09-08 US disclosed
US-20100029614-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2010-02-04 US disclosed
US-7598261-B2 Spirocyclic heterocyclic derivatives and methods of their use ADOLOR CORPORATION (US) 2009-10-06 US disclosed
US-20080119452-A1 METHODS FOR ENHANCING COGNITIVE FUNCTION CALIXA THERAPEUTICS, INC. 2008-05-22 US disclosed
WO-2008033299-A2 USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION ADOLOR CORPORATION (US) 2008-03-20 WO disclosed
EP-1871761-A2 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE Adolor Corporation (US) 2008-01-02 EP disclosed
US-20060270695-A1 Spirocyclic heterocyclic derivatives and methods of their use CUBIST PHARMACEUTICALS, INC. 2006-11-30 US disclosed
WO-2006105442-A2 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2006-10-05 WO disclosed
US-20050239874-A1 Novel analgesic and immunomodulatory cannabinoids UNIVERSITY OF CONNECTICUT (US) 2005-10-27 US disclosed
US-6939977-B2 Analgesic and immunomodulatory cannabinoids THE UNIVERSITY OF CONNECTICUT (US) 2005-09-06 US disclosed
EP-1075470-B1 NOVEL ANALGESIC AND IMMUNOMODULATORY CANNABINOIDS UNIV CONNECTICUT (US) 2003-08-13 EP disclosed
US-20030120094-A1 For improved binding of CB1/CB2 receptors; side effects reduction NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-26 US disclosed
US-20010009965-A1 NOVEL ANALGESIC AND IMMUNOMODULATORY CANNABINOIDS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2001-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218186-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE OPRK1, OPRD1, OPRL1 ALDH1A1 259/4885CYP19A1 711/4885CALM1 1251/4885
US-20150094330-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR PTGER4, LTB4R2, LTB4R ALDH1A1 600/4885CYP19A1 1875/4885CALM1 3180/4885
US-20080119452-A1 METHODS FOR ENHANCING COGNITIVE FUNCTION CHAT, GRIN2C, GRIN2A ALDH1A1 1162/4885CYP19A1 1406/4885CALM1 391/4885
US-20100029614-A1 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE OPRK1, OPRD1, OPRL1 ALDH1A1 259/4885CYP19A1 711/4885CALM1 1251/4885
US-20060270695-A1 Spirocyclic heterocyclic derivatives and methods of their use OPRK1, OPRD1, OPRL1 ALDH1A1 259/4885CYP19A1 711/4885CALM1 1251/4885
US-20010009965-A1 NOVEL ANALGESIC AND IMMUNOMODULATORY CANNABINOIDS CNR1, CNR2, CHRNA1 ALDH1A1 2733/4885CYP19A1 920/4885CALM1 152/4885
US-20030120094-A1 For improved binding of CB1/CB2 receptors; side effects reduction CNR1, CNR2, CHRNA1 ALDH1A1 4204/4885CYP19A1 937/4885CALM1 240/4885
US-20050239874-A1 Novel analgesic and immunomodulatory cannabinoids CNR1, CNR2, NPY1R ALDH1A1 2172/4885CYP19A1 868/4885CALM1 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.